Comparing biote (BTMD) and The Competition

biote (NASDAQ:BTMD – Get Rating) is one of 58 public companies in the “Medicinals & botanicals” industry, but how does it compare to its peers? We will compare biote to similar businesses based on the strength of its risk, valuation, profitability, dividends, analyst recommendations, earnings and institutional ownership.

Earnings & Valuation

This table compares biote and its peers top-line revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
biote	$164.96 million	-$970,000.00	90.02
biote Competitors	$282.87 million	-$110.28 million	-1.74

biote’s peers have higher revenue, but lower earnings than biote. biote is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for biote and its peers, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
biote	0	0	5	0	3.00
biote Competitors	214	568	818	46	2.42

biote presently has a consensus price target of $10.40, indicating a potential upside of 92.59%. As a group, “Medicinals & botanicals” companies have a potential upside of 107.93%. Given biote’s peers higher probable upside, analysts plainly believe biote has less favorable growth aspects than its peers.

Profitability

This table compares biote and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
biote	56.20%	-46.62%	29.08%
biote Competitors	-10.38%	-101.91%	21.35%

Insider and Institutional Ownership

3.8% of biote shares are owned by institutional investors. Comparatively, 14.3% of shares of all “Medicinals & botanicals” companies are owned by institutional investors. 16.6% of biote shares are owned by company insiders. Comparatively, 21.8% of shares of all “Medicinals & botanicals” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Risk and Volatility

biote has a beta of 0.6, indicating that its share price is 40% less volatile than the S&P 500. Comparatively, biote’s peers have a beta of 1.16, indicating that their average share price is 16% more volatile than the S&P 500.

Summary

biote beats its peers on 7 of the 13 factors compared.

About biote

(Get Rating)

biote Corp. operates in medical practice-building business within the hormone optimization space. The company offers a platform for Biote-certified practitioners to optimize imbalances in their patient's hormone, vitamin, and mineral levels, as well as prescribe bioidentical hormone therapies and recommend dietary supplements. It also sells Biote-branded dietary supplements; and sterile pellet insertion kits for men and women. The company was founded in 2011 and is headquartered in Irvine, Texas.